Immutep (IMMP) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChart

IMMP Stock Forecast


Immutep stock forecast is as follows: an average price target of $8.00 (represents a 214.96% upside from IMMP’s last price of $2.54) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

IMMP Price Target


The average price target for Immutep (IMMP) is $8.00 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $10.00 to $6.00. This represents a potential 214.96% upside from IMMP's last price of $2.54.

IMMP Analyst Ratings


Buy

According to 1 Wall Street analysts, Immutep's rating consensus is 'Buy'. The analyst rating breakdown for IMMP stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Immutep Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jun 27, 2024Joel BeattyRobert W. Baird$6.00$2.77116.61%136.22%
May 17, 2024Naureen QuibriaCapital One Financial$10.00$2.92242.47%293.70%
Row per page
Go to

The latest Immutep stock forecast, released on Jun 27, 2024 by Joel Beatty from Robert W. Baird, set a price target of $6.00, which represents a 116.61% increase from the stock price at the time of the forecast ($2.77), and a 136.22% increase from IMMP last price ($2.54).

Immutep Price Target by Period


1M3M12M
# Anlaysts-12
Avg Price Target-$6.00$8.00
Last Closing Price$2.54$2.54$2.54
Upside/Downside-100.00%136.22%214.96%

In the current month, the average price target of Immutep stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Immutep's last price of $2.54. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
May 18, 2023Maxim GroupBuyBuyHold
Row per page
Go to

Immutep's last stock rating was published by Maxim Group on May 18, 2023. The company gave IMMP a "Buy" rating, the same as its previous rate.

Immutep Financial Forecast


Immutep Revenue Forecast

Sep 24Jun 24Mar 24Dec 23Mar 16Dec 15
Revenue------
Avg Forecast-$2.73M$2.18M$1.96M$1.17M$1.17M
High Forecast-$2.73M$2.18M$1.96M$1.17M$1.17M
Low Forecast-$2.73M$2.18M$1.96M$1.17M$1.17M
# Analysts----33
Surprise %------

Immutep's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. IMMP's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Immutep EBITDA Forecast

Sep 24Jun 24Mar 24Dec 23Mar 16Dec 15
# Analysts----33
EBITDA------
Avg Forecast-$-1.64M$-2.18M$-1.18M$-1.17M$-1.17M
High Forecast-$-1.64M$-2.18M$-1.18M$-1.17M$-1.17M
Low Forecast-$-1.64M$-2.18M$-1.18M$-1.17M$-1.17M
Surprise %------

undefined analysts predict IMMP's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Immutep's previous annual EBITDA (undefined) of $NaN.

Immutep Net Income Forecast

Sep 24Jun 24Mar 24Dec 23Mar 16Dec 15
# Analysts----33
Net Income------
Avg Forecast$2.79B$-227.64M$2.86B$-244.22M--
High Forecast$2.79B$-227.64M$2.86B$-244.22M--
Low Forecast$2.79B$-227.64M$2.86B$-244.22M--
Surprise %------

Immutep's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IMMP's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Immutep SG&A Forecast

Sep 24Jun 24Mar 24Dec 23Mar 16Dec 15
# Analysts----33
SG&A------
Avg Forecast-$27.21M$40.43M$19.50M$21.67M$21.67M
High Forecast-$27.21M$40.43M$19.50M$21.67M$21.67M
Low Forecast-$27.21M$40.43M$19.50M$21.67M$21.67M
Surprise %------

Immutep's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to IMMP last annual SG&A of $NaN (undefined).

Immutep EPS Forecast

Sep 24Jun 24Mar 24Dec 23Mar 16Dec 15
# Analysts----33
EPS------
Avg Forecast$2.29$-0.19$2.39$-0.20--
High Forecast$2.29$-0.19$2.39$-0.20--
Low Forecast$2.29$-0.19$2.39$-0.20--
Surprise %------

According to undefined Wall Street analysts, Immutep's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IMMP previous annual EPS of $NaN (undefined).

Immutep Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
EFTReFFECTOR Therapeutics$0.04$5.5013650.00%Buy
ELEVElevation Oncology$0.63$9.001328.57%Buy
IMMPImmutep$2.54$8.00214.96%Buy
ZURAZura Bio$3.62$5.0038.12%Buy
VECTVectivBio$16.87$18.006.70%Buy

IMMP Forecast FAQ


Yes, according to 1 Wall Street analysts, Immutep (IMMP) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of IMMP's total ratings.

Immutep (IMMP) average price target is $8 with a range of $6 to $10, implying a 214.96% from its last price of $2.54. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for IMMP stock, the company can go up by 214.96% (from the last price of $2.54 to the average price target of $8), up by 293.70% based on the highest stock price target, and up by 136.22% based on the lowest stock price target.

IMMP's average twelve months analyst stock price target of $8 supports the claim that Immutep can reach $4 in the near future.

IMMP's analysts financial forecasts for the fiscal year (Jun 2024) are as follows: average revenue is $6.88M (high $6.88M, low $6.88M), average EBITDA is $-4.998M (high $-4.998M, low $-4.998M), average net income is $2.38B (high $2.38B, low $2.38B), average SG&A $87.14M (high $87.14M, low $87.14M), and average EPS is $2 (high $2, low $2).